These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37323179)

  • 1. Radiomic biomarkers from chest computed tomography are assistive in immunotherapy response prediction for non-small cell lung cancer.
    Schroeder KE; Acharya L; Mani H; Furqan M; Sieren JC
    Transl Lung Cancer Res; 2023 May; 12(5):1023-1033. PubMed ID: 37323179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [CT-Based Weighted Radiomic Score Predicts Tumor Response to Immunotherapy in Non-Small Cell Lung Cancer].
    Zhu ZC; Chen MJ; Song L; Wang JH; Hu G; Han W; Tan WX; Zhou Z; Sui X; Song W; Jin ZY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Oct; 45(5):794-802. PubMed ID: 37674467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
    Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
    J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
    Yoon J; Suh YJ; Han K; Cho H; Lee HJ; Hur J; Choi BW
    Thorac Cancer; 2020 Apr; 11(4):993-1004. PubMed ID: 32043309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study.
    Wu S; Zhan W; Liu L; Xie D; Yao L; Yao H; Liao G; Huang L; Zhou Y; You P; Huang Z; Li Q; Xu B; Wang S; Wang G; Zhang DK; Qiao G; Chan LW; Lanuti M; Zhou H
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37865396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer.
    Lim CH; Koh YW; Hyun SH; Lee SJ
    Anticancer Res; 2022 Dec; 42(12):5875-5884. PubMed ID: 36456151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer.
    Zhu Z; Chen M; Hu G; Pan Z; Han W; Tan W; Zhou Z; Wang M; Mao L; Li X; Sui X; Song L; Xu Y; Song W; Yu Y; Jin Z
    Eur Radiol; 2023 Jun; 33(6):3918-3930. PubMed ID: 36515714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of computed tomography radiomics combined with inflammation indices in predicting the efficacy of immunotherapy in patients with locally advanced and metastatic non-small cell lung cancer.
    Shao H; Zhu J; Shi L; Yao J; Wang Y; Ma C; Swierniak A; Ni B
    J Thorac Dis; 2024 May; 16(5):3213-3227. PubMed ID: 38883654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
    Zhang R; Hohenforst-Schmidt W; Steppert C; Sziklavari Z; Schmidkonz C; Atzinger A; Kuwert T; Klink T; Sterlacci W; Hartmann A; Vieth M; Förster S
    Nuklearmedizin; 2022 Oct; 61(5):385-393. PubMed ID: 35768005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting programmed death-ligand 1 expression level in non-small cell lung cancer using a combination of peritumoral and intratumoral radiomic features on computed tomography.
    Shiinoki T; Fujimoto K; Kawazoe Y; Yuasa Y; Kajima M; Manabe Y; Ono T; Hirano T; Matsunaga K; Tanaka H
    Biomed Phys Eng Express; 2022 Feb; 8(2):. PubMed ID: 35051908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by
    Li J; Ge S; Sang S; Hu C; Deng S
    Front Oncol; 2021; 11():789014. PubMed ID: 34976829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC.
    Bouhamama A; Leporq B; Faraz K; Foy JP; Boussageon M; Pérol M; Ortiz-Cuaran S; Ghiringhelli F; Saintigny P; Beuf O; Pilleul F
    Front Radiol; 2023; 3():1168448. PubMed ID: 37492391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
    Jiang M; Sun D; Guo Y; Guo Y; Xiao J; Wang L; Yao X
    Acad Radiol; 2020 Feb; 27(2):171-179. PubMed ID: 31147234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study.
    Jiang Z; Dong Y; Yang L; Lv Y; Dong S; Yuan S; Li D; Liu L
    J Digit Imaging; 2021 Oct; 34(5):1073-1085. PubMed ID: 34327623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the efficacy of immune checkpoint inhibitors monotherapy in advanced non-small cell lung cancer: a machine learning method based on multidimensional data.
    Liu N; Liang BL; Lu L; Zhang BQ; Sun JJ; Yang JT; Xu J; Song ZB; Shi L
    Neoplasma; 2023 Apr; 70(2):300-310. PubMed ID: 36812231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
    Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
    Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
    [No Abstract]   [Full Text] [Related]  

  • 20. Correlation between PD-L1 expression and radiomic features in early-stage lung adenocarcinomas manifesting as ground-glass nodules.
    Shi W; Yang Z; Zhu M; Zou C; Li J; Liang Z; Wang M; Yu H; Yang B; Wang Y; Li C; Wang Z; Zhao W; Chen L
    Front Oncol; 2022; 12():986579. PubMed ID: 36176405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.